{"name": "Pervasis Therapeutics",
 "permalink": "pervasis-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/pervasis-therapeutics",
 "homepage_url": "http://www.pervasistx.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@pervasistx.com",
 "phone_number": "617-621-3407",
 "description": "Clinical stage company",
 "created_at": "Thu Sep 24 23:11:37 UTC 2009",
 "updated_at": "Sat Mar 05 00:56:05 UTC 2011",
 "overview": "\u003Cp\u003EPervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts \u00e2\u20ac\u201c the failure of which result in serious complications and a significant increase in medical costs. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       84],
      "assets/images/resized/0006/0780/60780v1-max-150x150.png"],
     [[193,
       109],
      "assets/images/resized/0006/0780/60780v1-max-250x250.png"],
     [[193,
       109],
      "assets/images/resized/0006/0780/60780v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Director",
    "person":
     {"first_name": "Ed",
      "last_name": "Kania",
      "permalink": "ed-kania",
      "image":
       {"available_sizes":
         [[[103,
            150],
           "assets/images/resized/0004/5473/45473v1-max-150x150.jpg"],
          [[160,
            232],
           "assets/images/resized/0004/5473/45473v1-max-250x250.jpg"],
          [[160,
            232],
           "assets/images/resized/0004/5473/45473v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$44.5M",
 "funding_rounds":
  [{"round_code": "c",
    "source_url": "http://news.prnewswire.com/ViewContent.aspx?ACCT=109\u0026STORY=/www/story/09-16-2009/0005094898\u0026EDATE=",
    "source_description": "Pervasis Therapeutics Announces $17 Million in Financing and New Board Member",
    "raised_amount": 17380000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 8,
    "funded_day": 31,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Flagship Ventures",
         "permalink": "flagship-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8188/28188v4-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0002/8188/28188v4-max-250x250.png"],
             [[323,
               74],
              "assets/images/resized/0002/8188/28188v4-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Highland Capital Partners",
         "permalink": "highland-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0001/0992/10992v7-max-150x150.jpg"],
             [[250,
               59],
              "assets/images/resized/0001/0992/10992v7-max-250x250.jpg"],
             [[450,
               106],
              "assets/images/resized/0001/0992/10992v7-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.pervasistx.com/news/pressReleases/2008_0115.html",
    "source_description": "Pervasis Therapeutics Closes Additional $9.75 Million in Financing",
    "raised_amount": 9750000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 1,
    "funded_day": 15,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Flagship Ventures",
         "permalink": "flagship-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8188/28188v4-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0002/8188/28188v4-max-250x250.png"],
             [[323,
               74],
              "assets/images/resized/0002/8188/28188v4-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Highland Capital Partners",
         "permalink": "highland-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0001/0992/10992v7-max-150x150.jpg"],
             [[250,
               59],
              "assets/images/resized/0001/0992/10992v7-max-250x250.jpg"],
             [[450,
               106],
              "assets/images/resized/0001/0992/10992v7-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Musket Research Associates",
         "permalink": "musket-research-associates",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "",
    "source_description": "EDGAR",
    "raised_amount": 17400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2005,
    "funded_month": 8,
    "funded_day": 26,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Highland Capital Partners",
         "permalink": "highland-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0001/0992/10992v7-max-150x150.jpg"],
             [[250,
               59],
              "assets/images/resized/0001/0992/10992v7-max-250x250.jpg"],
             [[450,
               106],
              "assets/images/resized/0001/0992/10992v7-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Flagship Ventures",
         "permalink": "flagship-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8188/28188v4-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0002/8188/28188v4-max-250x250.png"],
             [[323,
               74],
              "assets/images/resized/0002/8188/28188v4-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "One Kendall Square, Ste. B6101",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "expanding into oncology and considering additional financing from either a corporate partner or the venture capital community",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 20,
    "source_url": "http://www.masshightech.com/stories/2011/01/17/daily38-Pervasis-broadens-to-cancer-therapeutics-eyes-new-financings.html",
    "source_text": null,
    "source_description": "Pervasis broadens to cancer therapeutics, eyes new financings",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Pervasis Therapeutics",
      "permalink": "pervasis-therapeutics"}},
   {"description": "The U.S. Food and Drug Administration has granted fast track review status to Cambridge biotech Pervasis Therapeutics Inc. for Vascugel, its lead drug program",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 8,
    "source_url": "http://www.masshightech.com/stories/2011/02/07/daily26-Pervasis-hemodialysis-treatment-lands-FDA-fast-track-review.html",
    "source_text": null,
    "source_description": "Pervasis hemodialysis treatment lands FDA fast-track review",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Pervasis Therapeutics",
      "permalink": "pervasis-therapeutics"}},
   {"description": "won orphan drug designation from the European Commission for its lead drug Vascugel",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/02/28/daily31-Pervasis-drug-candidate-gets-EU-orphan-drug-status.html",
    "source_text": null,
    "source_description": "Pervasis drug candidate gets EU orphan drug status",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Pervasis Therapeutics",
      "permalink": "pervasis-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        117],
       "assets/images/resized/0006/2956/62956v1-max-150x150.jpg"],
      [[250,
        196],
       "assets/images/resized/0006/2956/62956v1-max-250x250.jpg"],
      [[450,
        353],
       "assets/images/resized/0006/2956/62956v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}